Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Endo to acquire NuPathe for $2.85 per share in cash (~$105 million) plus contingent rights of up to $3.15 per share tied to Zecuity net sales; Endo plans to…
Endo agreed to pay $105 million for NuPathe, gaining Zecuity, 'a single-use patch version of the painkiller sumatriptan' and the first approved prescription…
FDA formally withdrew approval of ZECUITY (sumatriptan iontophoretic transdermal system) at Teva's request after burn/scar safety reports prompted June…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Endo announced agreement to acquire NuPathe at $2.85/share cash (~$105M) + CVR up to $3.15/share (~$116M) tied to Zecuity sales. Endo deal terminated Jan 2014 in favor of Teva's superior $144M offer ($3.65/share).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Health Solutions Inc. / NuPathe Inc. (this deal) | 2013 | $271M | — |
| Endo Health Solutions Inc. / Paladin Labs Inc. | 2013 | $1.6B | 28 |
| Endo Health Solutions Inc. / Boca Pharmacal, LLC | 2014 | $225M | 21 |
| Endo Health Solutions Inc. / Boca Pharmacal, LLC | 2013 | $225M | 19 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2013 deals · Endo Health Solutions Inc. deals · Neurology deals